The FDA has issued emergency use authorization (EUA) to Terumo BCT (OTC:TRUMY;TYO:4543) and Marker Therapeutics for a blood purification and oxygenation system to treat patients with COVID-19. Lakewood, Colo.-based Terumo’s Spectra Optia apheresis system works with the Depuro D2000 adsorption cartridges made by Marker Therapeutics to reduce the number of cytokines and other inflammatory blood […]